Diagnosis of multiple myeloma on gene expression profiling

• US 7,308,364 B2
• Filed: 06/04/2003
• Issued: 12/11/2007
• Est. Priority Date: 11/07/2001
• Status: Expired due to Term

• Current Assignee: Bioventures, LLC
• Original Assignee: University of Arkansas for Medical Sciences (University of Kansas)
• Inventors: Zhan, Fenghuang, Barlogie, Bart, Shaughnessy, John D.
• Primary Examiner(s): Zhou; Shubo (Joe)
• Application Number:
  US10/454,263
• Publication Number:
  US 20040009523A1
• Time in Patent Office: 1,651 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Gene expression profiling between normal B cells/plasma cells and multiple myeloma cells revealed four distinct subgroups of multiple myeloma plasma cells that have significant correlation with clinical characteristics known to be associated with poor prognosis. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognostics for the four subgroups of multiple myeloma based on the expression of 24 genes were also established. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. The development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.

Claims

1. A method of diagnosis for multiple myeloma, comprising the steps of:

isolating plasma cells from an individual;

examining expression of a group of 14 genes within said plasma cells, said 14 genes identified by SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13 and SEQ ID NO. 14,

performing statistical analysis on the expression levels of said genes, wherein a statistically significant value, representing collectively the expression levels of said genes, of said analysis indicates that said individual has multiple myeloma.

2. The method of claim 1, wherein the expression of said 14 genes is examined at the nucleic acid level or protein level.